LAVA Medtech Acquisition Corp. Class A Common Stock
LVAC
LVAC was delisted on the 10th of May, 2023.
47 hedge funds and large institutions have $94.4M invested in LAVA Medtech Acquisition Corp. Class A Common Stock in 2022 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 2 closing their positions.
350% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 2
18% more funds holding
Funds holding: 40 → 47 (+7)
5% more capital invested
Capital invested by funds: $89.7M → $94.4M (+$4.71M)
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Saba Capital Management
New York
|
+$4.99M |
| 2 |
JP Morgan Chase
New York
|
+$3.99M |
| 3 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$3.99M |
| 4 |
Millennium Management
New York
|
+$1.55M |
| 5 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$749K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Beryl Capital Management
Redondo Beach,
California
|
-$9.94M |
| 2 |
CCM
Context Capital Management
Lajolla,
California
|
-$2.25M |
| 3 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$29.1K |
| 4 |
FTCM
Fir Tree Capital Management
New York
|
-$4.99K |
| 5 |
Walleye Capital
New York
|
-$2K |
LVAC Hedge Fund Activity: Q2 2022 in Review
47 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in LAVA Medtech Acquisition Corp. Class A Common Stock (LVAC) for Q2 2022, worth a combined $94.4M — up 5.3% from $89.7M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new LVAC positions and 2 closed out — a net gain of 7 holders — while 6 added to existing stakes and 6 trimmed.
The largest buyer was Saba Capital Management, adding an estimated $4.99M. The largest seller was Beryl Capital Management, exiting entirely with an estimated $9.94M sold.
- 47 institutional investors held LAVA Medtech Acquisition Corp. Class A Common Stock (LVAC) as of Q2 2022, up from 40 in Q1 2022.
- Funds reported $94.4M of LAVA Medtech Acquisition Corp. Class A Common Stock stock for Q2 2022, up 5.3% quarter-over-quarter.
- 9 funds opened new LAVA Medtech Acquisition Corp. Class A Common Stock positions in Q2 2022 and 2 closed out, a net change of +7 holders.
- The largest LAVA Medtech Acquisition Corp. Class A Common Stock buyer in Q2 2022 was Saba Capital Management, an estimated $4.99M added.
- The largest LAVA Medtech Acquisition Corp. Class A Common Stock seller in Q2 2022 was Beryl Capital Management, an estimated $9.94M sold.
Based on aggregated 13F filings for Q2 2022.